Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Grabs European Nod for Naldemedine
February 25, 2019
- Daiichi Sankyo to Shake Up Organizations Focusing on Oncology R&D
February 25, 2019
- SanBio Vows to Continue Development of Stem Cell Therapy SB623 despite Setback: President
February 25, 2019
- Kyowa, Yoshitomi to Copromote Bipresso in Japan
February 22, 2019
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
- Japan Pharma Market Down 1.7% in 2018, with Maviret as Top-Selling Product: IQVIA Data
February 21, 2019
- Janssen Files Protease Inhibitor/NRTIs Combo for HIV Infection in Japan
February 21, 2019
- Ono/Seikagaku’s Novel Osteoarthritis Drug Hits Primary Goal in Japan PIII
February 20, 2019
- EA Pharma Grabs Japan Rights to Dr. Falk’s Liver Therapy
February 20, 2019
- Suzuken, Toho to Set Up Generic JV, Share Systems in Specialty Pharma Business
February 20, 2019
- Shionogi, FunPep Link to Joint Research for Antibody-Inducing Peptides in Pain Field
February 19, 2019
- Taiyo Forms Capital Alliance with Regenerative Medicine Biotech
February 19, 2019
- As Japan Goes Digital on Package Inserts, Distributors Fret Proposed Paper-Based Rule on “1st Delivery”
February 18, 2019
- Crysvita Shows Long-Term Benefits in Pediatric XLH Study
February 18, 2019
- Shire’s Product Sales Up 3.9% in 2018: Takeda
February 18, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Merck Serono Japan to Be Renamed “Merck Biopharma” in April
February 18, 2019
- Rexulti Misses Primary Goal in Global PIII for Bipolar I Disorder: Otsuka, Lundbeck
February 18, 2019
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…